AstraZeneca
| Type | Public |
| HQ | Cambridge, GB |
| Founded | 1999 |
| Size (employees) | 61,100 (est)+3% |
| Website | astrazeneca.com |
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at AstraZeneca
Leif Johansson
Non-Executive Chairman of the Board
Pascal Soriot
Executive Director and Chief Executive Officer
Marc Dunoyer
Executive Director and Chief Financial Officer
Rudy Markham
Senior Independent Non-Executive Director
Genevieve Berger
Non-Executive Director
Philip Broadley
Non-Executive Director
Report incorrect company information
AstraZeneca Office Locations
AstraZeneca has offices in Seattle, New Haven, Tampa, Jersey and in 166 other locations
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Wedel, DE
Wedel, Tinsdaler Weg 183
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
London, GB
15 Stanhope Gate
Report incorrect company information
AstraZeneca Financials and Metrics
AstraZeneca Revenue
AstraZeneca's revenue was reported to be £22.46 b in FY, 2017
| GBP | |
|---|---|
Revenue (FY, 2017) | 22.5b |
Gross profit (FY, 2017) | 18.1b |
Gross profit margin (FY, 2017), % | 80.8% |
Net income (FY, 2017) | 2.9b |
EBITDA (FY, 2017) | 6.7b |
EBIT (FY, 2017) | 3.7b |
Market capitalization (15-Oct-2018) | 94.9b |
Closing stock price (15-Oct-2018) | 37.5 |
Cash (31-Dec-2017) | 3.3b |
EV | 93.9b |
AstraZeneca's current market capitalization is $94.9 b.
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.4b | 5.2b | 5.5b | 11.4b | 12.1b | 11.4b | 11.1b | 10.5b | 11.5b | 14.0b | 13.5b | 14.8b | 19.8b | 16.9b | 19.6b | 19.1b | 23.0b | 22.5b |
Revenue growth, % | 1% | (9%) | (10%) | |||||||||||||||
Cost of goods sold | 2.2b | 2.0b | 2.2b | 3.7b | 3.7b | 3.1b | 2.8b | 2.5b | 2.8b | 3.1b | 2.7b | 3.2b | 4.1b | 3.5b | 4.3b | 3.6b | 4.1b | 4.3b |
Gross profit | 3.1b | 3.2b | 3.4b | 7.6b | 8.4b | 8.3b | 8.3b | 8.0b | 8.7b | 10.8b | 10.8b | 11.6b | 15.7b | 13.4b | 15.3b | 15.5b | 18.9b | 18.1b |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 259.0m | 303.0m | 206.0m | 265.0m | 683.0m | 489.0m | 453.0m | 409.0m | 565.0m | 2.9b | 3.6b | 2.9b | 2.7b | 6.1b | 4.7b | 4.8b | 5.0b | 3.3b |
Accounts Receivable | 935.0m | 969.0m | 1.1b | 1.8b | 1.8b | 1.7b | 1.7b | 1.8b | 1.9b | 2.2b | 2.2b | 2.7b | 3.5b | 3.6b | 3.5b | 3.6b | 2.6b | 2.8b |
Inventories | 681.0m | 728.0m | 798.0m | 1.3b | 1.4b | 1.7b | 1.6b | 1.7b | 1.6b | 1.3b | 1.2b | 1.1b | 1.0b | 1.3b | 1.4b | 1.7b | 2.3b | 3.0b |
Current Assets | 3.0b | 2.9b | 2.7b | 6.1b | 7.0b | 6.8b | 7.6b | 7.2b | 7.7b | 8.0b | 8.7b | 8.6b | 10.0b | 13.2b | 12.2b | 12.3b | 13.0b | 12.9b |
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 655.0m | 736.0m | 715.0m | 704.0m | 1.7b | 2.1b | 1.8b | 1.7b | 2.1b | 2.8b | 3.1b | 2.8b | 3.8b | 1.7b | 913.3m | 2.2b | 3.4b | 2.9b |
Cash From Operating Activities | 1.1b | 1.2b | 1.2b | 1.9b | 2.8b | 2.6b | 3.5b | 2.4b | 3.2b | 3.9b | 3.9b | 3.8b | 5.5b | 4.9b | 5.2b | 4.0b | 4.1b | 3.6b |
Dividends Paid | 332.0m | 365.0m | 399.0m | 764.0m | 1.9b | 850.0m | 753.0m | 754.0m | 833.0m | 976.0m | 1.1b | 1.3b | 1.7b | 2.6b | 2.7b | |||
Cash From Financing Activities | (39.0m) | (32.0m) | (96.0m) | (112.0m) | (267.0m) | (665.0m) | (794.0m) | (811.0m) | (740.0m) | (2.7b) | (2.7b) | 3.0b | (4.0b) | (2.0b) | (2.0b) | 3.4b | (1.3b) | (2.9b) |
| GBP | Y, 2017 |
|---|---|
EV/EBITDA | 14 x |
EV/EBIT | 25.5 x |
EV/CFO | 26.2 x |
Revenue/Employee | 367.7k |
Debt/Equity | 0.2 x |
Financial Leverage | 4.2 x |
AstraZeneca Revenue Breakdown
AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases
Report incorrect company information
AstraZeneca Online and Social Media Presence
148.3k Twitter followers
AstraZeneca has 148.3k Twitter Followers. The number of followers has increased 1.2% month over month and increased 1.9% quarter over quarter
28.42k Facebook likes
AstraZeneca has 28.42k Facebook Likes. The number of likes has increased 1.1% month over month and increased 2% quarter over quarter
Report incorrect company information
AstraZeneca News and Updates
October 17, 2018
Women’s Health Global Market 2018 Top Key Players – Agile Therapeutics, Allergan , Amgen , AstraZeneca , Bayer AG , Bristol-Myers Squibb Company and Forecast to 2023
Wiseguyreports.Com Added New Market Research Report On -“Women’s Health Market 2018 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday
October 16, 2018
Cough Remedies 2018 Global Market Key Players – Johnson & Johnson, Reckitt Benckiser, Bayer, GlaxoSmithKline, AstraZeneca – Analysis and Forecast to 2023
WiseGuyRerports.com Presents “Global Cough Remedies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
October 15, 2018
AstraZeneca will keep UK investment freeze if no Brexit clarity
AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.
October 15, 2018
AstraZeneca halts UK investments due to Brexit - Le Monde
PARIS (Reuters) - AstraZeneca has suspended investments in Britain due to the lack of clarity over the country's departure from the European Union, the pharmaceutical firm's non-executive chairman Leif Johansson told France's Le Monde newspaper.
October 15, 2018
AstraZeneca halts UK investments due to Brexit uncertainties - Le Monde
AstraZeneca has suspended
investments in Britain due to the lack of clarity over the
country's departure from the European Union, the pharmaceutical
firm's non-executive chairman Leif Johansson told France's Le
Monde newspaper.
October 15, 2018
Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.
Report incorrect company information
AstraZeneca Blogs
AstraZeneca Company Life and Culture
Report incorrect company information